Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.

Nature genetics - 1 Nov 2016

Riaz Nadeem, Havel Jonathan J, Kendall Sviatoslav M, Makarov Vladimir, Walsh Logan A, Desrichard Alexis, Weinhold Nils, Chan Timothy A

Abstract excerpt

Immune checkpoint blockade has shown significant promise as an anticancer treatment, yet the determinants of response are not completely understood. Here we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival after anti-CTLA4 immunotherapy in two independent cohorts of patients with melanoma (n = 174). Interestingly, serpins are homologs of the well-known ovalbumin antigen and are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Serpins
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cohort Studies

Share to Ipilimumab

Share to Melanoma

Share to Mutation

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27668655
DOI: 10.1038/ng.3677
PMCID: PMC5553281

Genes

CTLA4
SERPINB3
SERPINB4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.PMID 27668655Read ↗

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanomaSemantic proximity Read ↗

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.Semantic proximity Read ↗

Membrane-Localized Mutations Predict the Efficacy of Cancer ImmunotherapySemantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.Semantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.Semantic proximity Read ↗

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.Semantic proximity Read ↗

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.